ConSynance Therapeutics on Tuesday has reported positive results from its Phase I trial of CSTI-500, a first-in-class drug for the rare central nervous system disorder (CNS).
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...